Inhibrx is a biotech company developing novel biologic therapeutic candidates, including INBRX-109 for cancer treatment, INBRX-105 for solid tumors, and INBRX-101 for AAT deficiency. They also offer INBRX-106 for oncology indications. Founded in 2010, the company is based in La Jolla, California.